(AMGN) Amgen - Ratings and Ratios
Arthritis Medication, Psoriasis Treatment, Osteoporosis Therapy, Cancer Treatment, Cardiovascular Therapy
AMGN EPS (Earnings per Share)
AMGN Revenue
Description: AMGN Amgen
Amgen Inc. is a leading biotechnology company that develops and delivers innovative human therapeutics worldwide, focusing on treating various serious illnesses including rheumatoid arthritis, psoriasis, osteoporosis, and certain types of cancer. Their diverse product portfolio includes blockbuster drugs such as Enbrel, Otezla, Prolia, and Repatha, among others, which are distributed through pharmaceutical wholesale distributors and direct-to-consumer channels.
From a business perspective, Amgen has established strategic collaborations with major pharmaceutical companies like AstraZeneca, Novartis, and UCB to co-develop and commercialize several key products, enhancing their pipeline and market reach. This approach not only diversifies their revenue streams but also underscores their commitment to advancing therapeutic options through partnerships.
Key Performance Indicators (KPIs) that are crucial for evaluating Amgens performance include their revenue growth, driven significantly by their top-selling products; their research and development (R&D) pipeline, which is vital for sustaining innovation and addressing unmet medical needs; and their profit margins, reflecting the companys operational efficiency. Additionally, metrics such as Return on Equity (RoE) of 92.94% indicate strong financial health and the ability to generate profits from shareholder equity. The companys forward P/E ratio of 14.20 suggests expectations of future growth, although their current P/E of 27.38 may indicate a relatively high valuation compared to projected earnings.
Amgens operational efficiency, coupled with their robust product portfolio and strategic partnerships, positions them well within the competitive biotechnology landscape. Their commitment to R&D is a critical driver of long-term value creation, with a focus on addressing significant unmet medical needs. As the company continues to execute on its pipeline and expand its market presence, investors and analysts will be closely monitoring key financial metrics, product approvals, and market dynamics to assess their future prospects.
Additional Sources for AMGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
AMGN Stock Overview
Market Cap in USD | 163,608m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 1983-06-17 |
AMGN Stock Ratings
Growth Rating | 28.0 |
Fundamental | 54.4 |
Dividend Rating | 68.1 |
Rel. Strength | 3.84 |
Analysts | 3.63 of 5 |
Fair Price Momentum | 292.88 USD |
Fair Price DCF | 425.29 USD |
AMGN Dividends
Dividend Yield 12m | 3.12% |
Yield on Cost 5y | 4.15% |
Annual Growth 5y | 7.06% |
Payout Consistency | 100.0% |
Payout Ratio | 44.6% |
AMGN Growth Ratios
Growth Correlation 3m | 69.5% |
Growth Correlation 12m | -53.9% |
Growth Correlation 5y | 84.8% |
CAGR 5y | 5.96% |
CAGR/Max DD 5y | 0.24 |
Sharpe Ratio 12m | 0.56 |
Alpha | -16.33 |
Beta | 0.386 |
Volatility | 24.43% |
Current Volume | 1725.4k |
Average Volume 20d | 2121.3k |
Stop Loss | 289.3 (-3%) |
As of July 18, 2025, the stock is trading at USD 298.25 with a total of 1,725,441 shares traded.
Over the past week, the price has changed by -0.71%, over one month by +2.83%, over three months by +8.51% and over the past year by -8.28%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Amgen (NASDAQ:AMGN) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 54.42 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMGN is around 292.88 USD . This means that AMGN is currently overvalued and has a potential downside of -1.8%.
Amgen has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold AMGN.
- Strong Buy: 10
- Buy: 5
- Hold: 14
- Sell: 1
- Strong Sell: 2
According to our own proprietary Forecast Model, AMGN Amgen will be worth about 317.5 in July 2026. The stock is currently trading at 298.25. This means that the stock has a potential upside of +6.46%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 314.3 | 5.4% |
Analysts Target Price | 315 | 5.6% |
ValueRay Target Price | 317.5 | 6.5% |